Journals / Türk Oftalmoloji Dergisi / 2012 / Cilt: 42 - Sayı: 6

Etiopathogenesis of retinopathy of prematurity

Prematüre retinopatisinde etiyopatogenez

Pages
479–483
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Recently, more profound understanding of the specific effects of molecules such as insulin-like growth factor-1 (IGF-1), erythropoietin (EPO), and vascular endothelial growth factor (VEGF) that play a role in the etiopathogenesis of ROP is suggested, and by determining the levels of these factors in the blood of premature infants, screening of infants with definitive blood levels of these factors is recommended.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In spite of current treatment methods, retinopathy of prematurity (ROP) is one of the most important reasons of blindness.
📊
Key Findings & Data:Increased number of newborn intensive care units and technological improvements lead to survival of increased number of immature infants which in turn leads to increased number of premature infants to be screened.
💡
Conclusion & Impact:Recently, more profound understanding of the specific effects of molecules such as insulin-like growth factor-1 (IGF-1), erythropoietin (EPO), and vascular endothelial growth factor (VEGF) that play a role in the etiopathogenesis of ROP is suggested, and by determining the levels of these factors in the blood of premature infants, screening of infants with definitive blood levels of these factors is recommended.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

In spite of current treatment methods, retinopathy of prematurity (ROP) is one of the most important reasons of blindness. Increased number of newborn intensive care units and technological improvements lead to survival of increased number of immature infants which in turn leads to increased number of premature infants to be screened. Recently, more profound understanding of the specific effects of molecules such as insulin-like growth factor-1 (IGF-1), erythropoietin (EPO), and vascular endothelial growth factor (VEGF) that play a role in the etiopathogenesis of ROP is suggested, and by determining the levels of these factors in the blood of premature infants, screening of infants with definitive blood levels of these factors is recommended. The aim of this review is to evaluate etiopathogenesis of ROP disease and to determine the specific mediators that play a role in the pathogenesis of ROP disease. Understanding the pathogenesis of ROP may induce changes in screening, monitoring, and treatment protocols.

Özet

rematüre retinopatisi (PR) güncel tedavi yöntemlerine rağmen çocuklarda körlüğün en önemli sebebidir. Yenidoğan yoğun bakım ünitelerinin yaygınlaşması ve teknolojik gelişmelerle birlikte daha fazla sayıda ve daha gelişmemiş bebeklerin yaşatılması mümkün olmaktadır, bu da taranması gereken prematür bebek sayısını arttırmaktadır. Bu nedenle son zamanlarda PR’nin etyopatogenezinde rol oynayan insülin benzeri büyüme faktörü (IGF-1), eritropoetin (EPO), vasküler endotelyal büyüme faktörü (VEGF) gibi moleküllerin patogenezdeki rollerinin tam anlaşılması ve bu faktörlerin kan seviyelerinin tespit edilerek kan değerleri belirli seviyelerde olan bebeklerin taranması fikri gündemdedir. Bu derlemedeki amacımız güncel bilgiler ışığında PR’nin etyopatogenezini ve etyopatogenezde rol alan faktörleri tekrar değerlendirmektir. PR’nin etyopatogenezinin anlaşılması tarama, takip ve tedavi protokollerinin yakın zamanda yenilenmesini gündeme getirebilir.

🔖

Cite This Article

BALCI, S. Y., ŞAHİN, Ö. Y. (2022). Etiopathogenesis of retinopathy of prematurity. Türk Oftalmoloji Dergisi, Cilt: 42 - Sayı: 6, 479–483. https://ajindex.com/articles/638278

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Steinkuller PG, Du L, Gilbert C, Foster A, Collins ML, Coats DK. Childhood blindness. J AAPOS. 1999
  2. Kocur I, Resnikoff S. Visual impairment and blindness in Europe and their prevention. Br J Ophthalmol. 2002
  3. Gilbert C, Rahi J, Eckstein M, O'Sullivan J, Foster A. Retinopathy of prematurity in middle income countries. Lancet. 1997
  4. 12–4. 4. Gilbert C, Fielder A, Gordillo L, et al. Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs. Pediatrics. 2005
  5. e518-25. 5. Section on Ophthalmology American Academy of Pediatrics
  6. American Academy of Ophthalmology
  7. American Association for Pediatric Ophthalmology and Strabismus. Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2006
  8. Akman I, Demirel U, Yenice O, Ilerisoy H, Kazokoğlu H, Ozek E. Screening criteria for retinopathy of prematurity in developing countries. Eur J Ophthalmol. 2010
  9. Mutlu FM, Altinsoy HI, Mumcuoglu T, et al. Screening for retinopathy of prematurity in a tertiary care newborn unit in Turkey: frequency, outcomes, and risk factor analysis. J Pediatr Ophthalmol Strabismus. 2008
  10. Hellström A, Engström E, Hård AL, et al. Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics. 2003
  11. Pérez-Muñuzuri A, Fernández-Lorenzo JR, Couce-Pico ML, Blanco-Teijeiro MJ, Fraga-Bermúdez JM. Serum levels of IGF1 are a useful predictor of retinopathy of prematurity. Acta Paediatr. 2010
  12. Çetinkaya M, Köksal N, Özkan H, Özmen AT. Prematüre Retinopatisi ile Serum İnsülin Benzeri Büyüme Faktörü-1 Düzeyleri Arasındaki İlişki. Güncel Pediatri 2008
  13. Bierer R, Peceny MC, Hartenberger CH, Ohls RK. Erythropoietin concentrations and neurodevelopmental outcome in preterm infants. Pediatrics. 2006
  14. Sato T, Kusaka S, Shimojo H, Fujikado T. Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity. Ophthalmology. 2009
  15. Kwinta P, Bik-Multanowski M, Mitkowska Z, Tomasik T, Pietrzyk JJ. The clinical role of vascular endothelial growth factor (VEGF) system in the pathogenesis of retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2008
  16. Pieh C, Agostini H, Buschbeck C